Difference between revisions of "Bendamustine"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Nitrogen mustard, alkylator; bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring which forms electrophilic alkyl groups, resulting in interstrand DNA crosslinks, leading to cell death via several pathways in both quiescent and dividing cells.<ref name="insert">[http://www.treanda.com/pdf/TREANDA_final_PI.pdf Bendamustine (Treanda) package insert]</ref><ref>[[Media:Bendamustine.pdf | Bendamustine (Treanda) package insert (locally hosted backup)]]</ref><ref>[http://treanda.com/ Treanda manufacturer's website]</ref> | Class/mechanism: Nitrogen mustard, alkylator; bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring which forms electrophilic alkyl groups, resulting in interstrand DNA crosslinks, leading to cell death via several pathways in both quiescent and dividing cells.<ref name="insert">[http://www.treanda.com/pdf/TREANDA_final_PI.pdf Bendamustine (Treanda) package insert]</ref><ref>[[Media:Bendamustine.pdf | Bendamustine (Treanda) package insert (locally hosted backup)]]</ref><ref>[http://treanda.com/ Treanda manufacturer's website]</ref> | ||
| Line 7: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/treanda-bendamustine-342133 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/treanda-bendamustine-342133 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Aggressive Non-Hodgkin lymphoma]] | ||
| + | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
| + | *[[Follicular lymphoma]] | ||
| + | *[[Hairy cell leukemia]] | ||
| + | *[[Hodgkin lymphoma]] | ||
| + | *[[Mantle cell lymphoma]] | ||
| + | *[[Multiple myeloma]] | ||
| + | *[[T-cell lymphoma]] | ||
| + | *[[Waldenström macroglobulinemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 12: | Line 21: | ||
*Brief patient counseling information can be found on [http://www.treanda.com/pdf/TREANDA_final_PI.pdf#page=7 page 7 of the package insert]<ref name="insert"></ref> | *Brief patient counseling information can be found on [http://www.treanda.com/pdf/TREANDA_final_PI.pdf#page=7 page 7 of the package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/bendamustine-patient-drug-information Bendamustine (Treanda) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bendamustine-patient-drug-information Bendamustine (Treanda) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/bendamustine-patient-drug-information Bendamustine (Treanda) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bendamustine-patient-drug-information Bendamustine (Treanda) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 3/20/2008: Initial FDA approval "for the treatment of patients with [[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | chronic lymphocytic leukemia (CLL)]]." | ||
| + | * 4/22/2009: Additional indication for "Indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with [[Rituximab (Rituxan) | rituximab]] or a rituximab containing regimen." | ||
| + | |||
| + | ==Also known as== | ||
| + | Bendamustine Hydrochloride, Ribomustin, SDX-105, or Treakisym. | ||
==References== | ==References== | ||
| Line 25: | Line 41: | ||
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| + | [[Category:Hairy cell leukemia medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:T-cell lymphoma medications]] | [[Category:T-cell lymphoma medications]] | ||
| + | [[Category:Waldenström macroglobulinemia medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2008]] | ||
Revision as of 02:10, 28 October 2014
General information
Class/mechanism: Nitrogen mustard, alkylator; bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring which forms electrophilic alkyl groups, resulting in interstrand DNA crosslinks, leading to cell death via several pathways in both quiescent and dividing cells.[1][2][3]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Aggressive Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Follicular lymphoma
- Hairy cell leukemia
- Hodgkin lymphoma
- Mantle cell lymphoma
- Multiple myeloma
- T-cell lymphoma
- Waldenström macroglobulinemia
Patient drug information
- Bendamustine (Treanda) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on page 7 of the package insert[1]
- Bendamustine (Treanda) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 3/20/2008: Initial FDA approval "for the treatment of patients with chronic lymphocytic leukemia (CLL)."
- 4/22/2009: Additional indication for "Indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen."
Also known as
Bendamustine Hydrochloride, Ribomustin, SDX-105, or Treakisym.
References
Categories:
- Drug index
- Chemotherapy
- Vesicant chemotherapy
- Nitrogen mustards
- Alkylating agents
- Aggressive Non-Hodgkin lymphoma medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Follicular lymphoma medications
- Hairy cell leukemia medications
- Hodgkin lymphoma medications
- Mantle cell lymphoma medications
- Multiple myeloma medications
- T-cell lymphoma medications
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 2008